BioGaia launches entire adult health portfolio in Sweden for mouth and bone health

28 Jan 2021 --- BioGaia is launching its complete adult health portfolio in Sweden, with its BioGaia Osfortis for bone health and BioGaia Prodentis for the mouth now available on the domestic market.

“In line with our already communicated strategy to accelerate the roll-out of our products for adults, we are pleased to now be able to offer the entire adult health portfolio to Swedish consumers,” says Isabelle Ducellier, CEO of BioGaia.

“BioGaia is a Swedish company and it makes sense to strengthen our position in our home market. For many years we have been successfully selling our paediatric portfolio in Sweden, including our biggest product BioGaia Protectis drops, through our partner Semper. However, during the last couple of years we have seen a growing interest in our adult health products as well,” Ducellier tells NutritionInsight.

Probiotics for mouth and bones
BioGaia Osfortis capsules contain the clinically tested and patented lactic acid bacterium L. reuteri ATCC PTA 6475 and vitamin D3, which helps to maintain a normal bone structure. 

Meanwhile, BioGaia Prodentis contains the patented lactic acid bacteria L. reuteri DSM 17938 and ATCC PTA 5289 and has been tested in more than 50 clinical studies.

BioGaia Prodentis lozenges are available in around 40 countries worldwide. Some of its largest products are already on the Swedish market, but the new launch completes its portfolio.

BioGaia Osfortis for bone health and BioGaia Prodentis for the mouth complete Biogaia’s portfolio within the Swedish market.Other products include BioGaia Protectis, which are capsules and chewable tablets, available in several pack sizes and product variants. The tablets are also available with 10 or 20 mg of vitamin D3, which contributes to the normal function of the immune system.

In addition, the company offers BioGaia Gastrus chewable tablets with mandarin flavor. 

All products are sold via apotea.se and MEDS.se. In the future, the products will be available in more pharmacy chains, both online and in physical stores, the company says. 

Ever-expanding reach
BioGaia’s L.reuteri Protectis DSM 17938 probiotic strain has solid clinical data in babies with colic, and has also been found to reduce pain intensity and increase the number of pain-free days in children with functional abdominal pain (FAP), compared to a placebo.

For 2020, BioGaia reported a good start, with sales increasing by 7 percent to SEK 182.8 million (US$18.7 million), excluding foreign exchange effects. The company’s Gastrus food supplement is available in Australia through BioGaia’s distribution partner, Bio-Practica. 

“Regardless of how the COVID-19 pandemic develops, the situation will require that we continue to adapt during the year in order to meet the challenges it brings. We are convinced that our products play a key role in these times as well, and we will do everything in our power to make them available globally,” Ducellier notes.

“As a result of the pandemic, consumer interest in immune-related products, such as probiotics, has risen sharply. The fact that the number of online consumer reviews on probiotics increased by more than 100 per cent between June 2019 and June 2020 clearly illustrates this. Healthy aging is one of our focus areas and this has become even more important during the pandemic as the elderly are increasingly interested in staying healthy,” concludes Ducellier.

By Kristiana Lalou

To contact our editorial team please email us at editorial@cnsmedia.com